Nature Communications (Apr 2020)
Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer
Abstract
Dysregulation of mRNA alternative splicing is prevalent in cancers. Here, the authors characterized the landscape of aberrant alternative splicing during the development of prostate cancer, progression and therapeutic resistance and show that splicing modulator, E7107, reduces growth in castration-resistant prostate cancer.